Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01442337 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients
A Phase 2 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT01442337 is a Phase 2 study that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 21 participants.
The verdict
NCT01442337, a Phase 2 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of a single intravenous dose of ASP8597 in kidney transplant recipients.
Interventions
- DRUG Placebo
- DRUG ASP8597
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01442337
The ClinicalTrials.gov registry entry for NCT01442337 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01442337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01442337 about?
NCT01442337 is a clinical study titled "A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients". The purpose of this study is to evaluate the efficacy, safety and tolerability of a single intravenous dose of ASP8597 in kidney transplant recipients.
What is the current status of trial NCT01442337?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2011-12. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01442337?
The interventions under investigation include: Placebo (DRUG), ASP8597 (DRUG).
Who is sponsoring clinical trial NCT01442337?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.